236 TWELVE-WEEK COURSE OF PIFN-α-2A/RIBAVIRIN IS AN OPTIMIZED REGIMEN FOR TREATMENT OF HCV GENOTYPE 2 BUT NOT GENOTYPE 3 NON-CIRRHOTIC PATIENTS WITH RVR
Keyword(s):
2008 ◽
Vol 28
(4)
◽
pp. 397-404
◽
Keyword(s):
Keyword(s):
Keyword(s):
2015 ◽
Vol 148
(2)
◽
pp. 355-366.e1
◽
Keyword(s):
2014 ◽
Vol 60
(1)
◽
pp. S4-S5
◽
Keyword(s):